Contribution of individual PKC isoforms to breast cancer progression

IUBMB Life

Volumn 64, Issue 1, 2012, Pages 18-26

  Urtreger, Alejandro J ^a   Kazanietz, Marcelo G ^b   Bal De Kier Joffé, Elisa D ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

breast cancer; prognostic marker; Protein kinase C; tumor progression

Indexed keywords

APRINOCARSEN; ENZASTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA; PROTEIN KINASE C IOTA; PROTEIN KINASE C THETA; PROTEIN KINASE C ZETA; TAMOXIFEN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; DISEASE COURSE; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; LUNG METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; PHENOTYPE; PROTEIN KINASE C; PROTEIN STRUCTURE, TERTIARY;

EID: 84855468351     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.574     Document Type: Review

References (72)

1. Takai, Y., Kishimoto, A., Iwasa, Y., Kawahara, Y., Mori, T., et al. (1979) Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids. J. Biol. Chem. 254, 3692-3695.
2. Dekker, L. V., and, Parker, P. J., (1994) Protein kinase C-a question of specificity. Trends Biochem. Sci. 19, 73-77. (Pubitemid 24055564)
3. Nishizuka, Y., (1995) Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9, 484-496.
4. Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., et al. (1982) Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257, 7847-7851. (Pubitemid 12043279)
5. Way, K. J., Chou, E., and, King, G. L., (2000) Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol. Sci. 21, 181-187. (Pubitemid 30243200)
6. Griner, E. M., and, Kazanietz, M. G., (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer. 7, 281-294. (Pubitemid 46480971)
7. Prevostel, C., Alvaro, V., de Boisvilliers, F., Martin, A., Jaffiol, C., et al. (1995) The natural protein kinase C alpha mutant is present in human thyroid neoplasms. Oncogene 11, 669-674.
8. Knauf, J. A., Ward, L. S., Nikiforov, Y. E., Nikiforova, M., Puxeddu, E., et al. (2002) Isozyme-specific abnormalities of PKC in thyroid cancer: evidence for post-transcriptional changes in PKC epsilon. J. Clin. Endocrinol. Metab. 87, 2150-2159. (Pubitemid 34521502)
9. Gordge, P. C., Hulme, M. J., Clegg, R. A., and, Miller, W. R., (1996) Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur. J. Cancer. 32A, 2120-2126. (Pubitemid 26419463)
10. Ways, D. K., Kukoly, C. A., deVente, J., Hooker, J. L., Bryant, W. O., et al. (1995) MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. 95, 1906-1915.
11. Fields, A. P., and, Murray, N. R., (2008) Protein kinase C isozymes as therapeutic targets for treatment of human cancers. Adv. Enzyme Regul. 48, 166-178.
12. Coluccio Leskow, F., Krasnapolski, M. A., and, Urtreger, A. J., the pros and cons of targeting protein kinase c (PKC) in the management of cancer patients. Curr. Pharm. Biotechnol., in press.
13. Nakagawa, M., Oliva, J. L., Kothapalli, D., Fournier, A., Assoian, R. K., et al. (2005) Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase Cdelta-dependent induction of p21. J. Biol. Chem. 280, 33926-33934. (Pubitemid 41443112)
14. Diaz Bessone, M. I., Berardi, D. E., Campodonico, P. B., Todaro, L. B., Lothstein, L., et al. (2011) Involvement of PKC delta (PKCdelta) in the resistance against different doxorubicin analogs. Breast Cancer Res. Treat. 126, 577-587.
15. Grossoni, V. C., Falbo, K. B., Kazanietz, M. G., de Kier Joffe, E. D., and, Urtreger, A. J., (2007) Protein kinase C delta enhances proliferation and survival of murine mammary cells. Mol. Carcinog. 46, 381-390. (Pubitemid 46744458)
16. Blobe, G. C., Obeid, L. M., and, Hannun, Y. A., (1994) Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 13, 411-431.
17. Jiang, H., Luo, J. Q., Urano, T., Frankel, P., Lu, Z., et al. (1995) Involvement of Ral GTPase in v-Src-induced phospholipase D activation. Nature 378, 409-412.
18. Marshall, C. J., (1996) Cell signalling. Raf gets it together. Nature 383, 127-128. (Pubitemid 26303963)
19. Balendran, A., Hare, G. R., Kieloch, A., Williams, M. R., and, Alessi, D. R., (2000) Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 484, 217-223.
20. Urtreger, A. J., Grossoni, V. C., Falbo, K. B., Kazanietz, M. G., and, Bal de Kier Joffe, E. D., (2005) Atypical protein kinase C-zeta modulates clonogenicity, motility, and secretion of proteolytic enzymes in murine mammary cells. Mol. Carcinog. 42, 29-39. (Pubitemid 40041483)
21. Zhang, J., Anastasiadis, P. Z., Liu, Y., Thompson, E. A., Fields, A. P., (2004) Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J. Biol. Chem. 279, 22118-22123. (Pubitemid 38679404)
22. Pan, Q., Bao, L. W., Kleer, C. G., Sabel, M. S., Griffith, K. A., et al. (2005) Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. 65, 8366-8371. (Pubitemid 41330602)
23. Grossoni, V. C., Todaro, L. B., Kazanietz, M. G., de Kier Joffe, E. D., and, Urtreger, A. J., (2009) Opposite effects of protein kinase C beta1 (PKCbeta1) and PKCepsilon in the metastatic potential of a breast cancer murine model. Breast Cancer Res. Treat. 118, 469-480.
24. Jackson, D., Zheng, Y., Lyo, D., Shen, Y., Nakayama, K., et al. (2005) Suppression of cell migration by protein kinase Cdelta. Oncogene 24, 3067-3072. (Pubitemid 40675540)
25. Grossoni, V. C., Falbo, K. B., Mauro, L. V., Krasnapolski, M. A., Kazanietz, M. G., et al. (2007) Protein kinase C delta inhibits the production of proteolytic enzymes in murine mammary cells. Clin. Exp. Metastasis. 24, 513-520. (Pubitemid 47524809)
26. Lukashev, M. E., and, Werb, Z., (1998) ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8, 437-441. (Pubitemid 28529716)
27. Masso-Welch, P. A., Verstovsek, G., and, Ip, M. M., (1999) Alterations in the expression and localization of protein kinase C isoforms during mammary gland differentiation. Eur. J. Cell Biol. 78, 497-510. (Pubitemid 29385222)
28. Tanaka, Y., Gavrielides, M. V., Mitsuuchi, Y., Fujii, T., and, Kazanietz, M. G., (2003) Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J. Biol. Chem. 278, 33753-33762. (Pubitemid 37553209)
29. Jarzabek, K., Laudanski, P., Dzieciol, J., Dabrowska, M., and, Wolczynski, S., (2002) Protein kinase C involvement in proliferation and survival of breast cancer cells. Folia Histochem. Cytobiol. 40, 193-194. (Pubitemid 34477145)
30. Nakashima, S., (2002) Protein kinase C alpha (PKC alpha): regulation and biological function. J. Biochem. 132, 669-675. (Pubitemid 35408487)
31. Lahn, M., Kohler, G., Sundell, K., Su, C., Li, S., et al. (2004) Protein kinase C alpha expression in breast and ovarian cancer. Oncology 67, 1-10. (Pubitemid 39370344)
32. Tan, M., Li, P., Sun, M., Yin, G., and, Yu, D., (2006) Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 25, 3286-3295. (Pubitemid 43846313)
33. Kerfoot, C., Huang, W., and, Rotenberg, S. A., (2004) Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J. Histochem. Cytochem. 52, 419-422. (Pubitemid 38229108)
34. Frankel, L. B., Lykkesfeldt, A. E., Hansen, J. B., and, Stenvang, J., (2007) Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res. Treat. 104, 165-179. (Pubitemid 47084221)
35. Gill, P. K., Gescher, A., and, Gant, T. W., (2001) Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta. Eur. J. Biochem. 268, 4151-4157. (Pubitemid 32862875)
36. Lonne, G. K., Cornmark, L., Zahirovic, I. O., Landberg, G., Jirstrom, K., et al. PKCalpha expression is a marker for breast cancer aggressiveness. Mol. Cancer. 9, 76.
37. Parsons, M., Keppler, M. D., Kline, A., Messent, A., Humphries, M. J., et al. (2002) Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis. Mol. Cell Biol. 22, 5897-5911. (Pubitemid 34815838)
38. Perez White, B. E., Zhao, H., and, Tonetti, D. A., (2011) Overexpression of PKCα in T47D breast cancer cells induces migration via p120-catenin transcriptional downregulation. In: Proceedings of the American Association for Cancer Research (AACR). Philadelphia PA, pp 560-561, vol. 52.
39. Kim, J., Thorne, S. H., Sun, L., Huang, B., and, Mochly-Rosen, D., Sustained inhibition of PKCalpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 30, 323-333.
40. Platet, N., Prevostel, C., Derocq, D., Joubert, D., Rochefort, H., et al. (1998) Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int. J. Cancer. 75, 750-756. (Pubitemid 28145823)
41. Assender, J. W., Gee, J. M., Lewis, I., Ellis, I. O., Robertson, J. F., et al. (2007) Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J. Clin. Pathol. 60, 1216-1221. (Pubitemid 350084541)
42. Li, K., and, Zhang, J., (2001) ISIS-3521. Isis Pharmaceuticals. Curr. Opin. Investig. Drugs. 2, 1454-1461.
43. Mackay, H. J., and, Twelves, C. J., (2003) Protein kinase C: a target for anticancer drugs? Endocr. Relat. Cancer. 10, 389-396. (Pubitemid 37267557)
44. Li, H., and, Weinstein, I. B., (2006) Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res. 66, 11399-11408. (Pubitemid 46009971)
45. Sledge, G. W., Jr., and, Gokmen-Polar, Y., (2006) Protein kinase C-beta as a therapeutic target in breast cancer. Semin. Oncol. 33, S15-S18.
46. Sledge, G. W., Jr., and, Gokmen-Polar, Y., (2006) Protein kinase C-beta as a therapeutic target in breast cancer. Semin. Oncol. 33, S15-S18.
47. Urtreger, A., Porro, F., Puricelli, L., Werbajh, S., Baralle, F. E., et al. (1998) Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. Int. J. Cancer. 78, 233-241. (Pubitemid 28443182)
48. Liu, J. F., Crepin, M., Liu, J. M., Barritault, D., and, Ledoux, D., (2002) FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem. Biophys. Res. Commun. 293, 1174-1182. (Pubitemid 34681065)
49. Kiley, S. C., Clark, K. J., Duddy, S. K., Welch, D. R., and, Jaken, S., (1999) Increased protein kinase C delta in mammary tumor cells: relationship to transformation and metastatic progression. Oncogene 18, 6748-6757.
50. Lonne, G. K., Masoumi, K. C., Lennartsson, J., and, Larsson, C., (2009) Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. J. Biol. Chem. 284, 33456-33465.
51. Vucenik, I., Ramakrishna, G., Tantivejkul, K., Anderson, L. M., and, Ramljak, D., (2005) Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res. Treat. 91, 35-45. (Pubitemid 40684937)
52. Fujii, T., Nakamura, A. M., Yokoyama, G., Yamaguchi, M., Tayama, K., et al. (2005) Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells. Oncol. Rep. 14, 489-494.
53. Nabha, S. M., Glaros, S., Hong, M., Lykkesfeldt, A. E., Schiff, R., et al. (2005) Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24, 3166-3176. (Pubitemid 40695085)
54. Lindemann, R. K., Braig, M., Ballschmieter, P., Guise, T. A., Nordheim, A., et al. (2003) Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int. J. Oncol. 22, 799-805.
55. Toton, E., Ignatowicz, E., Skrzeczkowska, K., and, Rybczynska, M., (2011) Protein kinase Cepsilon as a cancer marker and target for anticancer therapy. Pharmacol. Rep. 63, 19-29.
56. Pan, Q., Bao, L. W., Teknos, T. N., and, Merajver, S. D., (2006) Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res. 66, 9379-9384. (Pubitemid 44623633)
57. Lavie, Y., Zhang, Z. C., Cao, H. T., Han, T. Y., Jones, R. C., et al. (1998) Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int. J. Cancer. 77, 928-932. (Pubitemid 28378145)
58. Masso-Welch, P. A., Verstovsek, G., Darcy, K., Tagliarino, C., and, Ip, M. M., (1998) Protein kinase C eta upregulation and secretion during postnatal rat mammary gland differentiation. Eur. J. Cell Biol. 77, 48-59. (Pubitemid 28472737)
59. Karp, G., Maissel, A., and, Livneh, E., (2007) Hormonal regulation of PKC: estrogen up-regulates PKCeta expression in estrogen-responsive breast cancer cells. Cancer Lett. 246, 173-181. (Pubitemid 44959387)
60. Rotem-Dai, N., Oberkovitz, G., Abu-Ghanem, S., and, Livneh, E., (2009) PKCeta confers protection against apoptosis by inhibiting the pro-apoptotic JNK activity in MCF-7 cells. Exp. Cell Res. 315, 2616-2623.
61. Masso-Welch, P. A., Winston, J. S., Edge, S., Darcy, K. M., Asch, H., et al. (2001) Altered expression and localization of PKC eta in human breast tumors. Breast Cancer Res. Treat. 68, 211-223. (Pubitemid 33702317)
62. Beck, J., Bohnet, B., Brugger, D., Bader, P., Dietl, J., et al. (1998) Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression. Br. J. Cancer. 77, 87-91. (Pubitemid 28029777)
63. Belguise, K., and, Sonenshein, G. E., (2007) PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. J. Clin. Invest. 117, 4009-4021. (Pubitemid 350224110)
64. Nakanishi, H., Brewer, K. A., and, Exton, J. H., (1993) Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 268, 13-16. (Pubitemid 23021278)
65. Chou, M. M., Hou, W., Johnson, J., Graham, L. K., Lee, M. H., et al. (1998) Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr. Biol. 8, 1069-1077. (Pubitemid 28451031)
66. Fields, A. P., and, Regala, R. P., (2007) Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol. Res. 55, 487-497. (Pubitemid 46962307)
67. Suzuki, A., Akimoto, K., and, Ohno, S., (2003) Protein kinase C lambda/iota (PKClambda/iota): a PKC isotype essential for the development of multicellular organisms. J. Biochem. 133, 9-16. (Pubitemid 36240973)
68. Castoria, G., Migliaccio, A., Di Domenico, M., Lombardi, M., de Falco, A., et al. (2004) Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells. Mol. Cell Biol. 24, 7643-7653. (Pubitemid 39121490)
69. Liu, Y., Wang, J., Wu, M., Wan, W., Sun, R., et al. (2009) Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol. Cancer Res. 7, 944-954.
70. Sun, R., Gao, P., Chen, L., Ma, D., Wang, J., et al. (2005) Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res. 65, 1433-1441. (Pubitemid 40270172)
71. Kampfer, S., Windegger, M., Hochholdinger, F., Schwaiger, W., Pestell, R. G., et al. (2001) Protein kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras. J. Biol. Chem. 276, 42834-42842.
72. Restall, I. J., Paget, J. A., Daneshmand, M., Ain, M. S., Islam, S., et al. (2011) Repression of cancer senescence by PKC. In proceedings of the American Association for Cancer Research (AACR), Philadelphia PA. pp. 294-295, vol. 52.